For example, inhibitors of mutant FMS-like tyrosine kinase 3 (FLT3) and isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) are effective in increasing the response rates and improving the prognosis of patients with AML [7–9]. The gene discussed is IDH1; the disease is acute myeloid leukemia.